|
|
|
| Effect of Yiqi Huoxue Shengji Prescription on refractory wound healing and vessel regeneration |
| LUO Yuancheng ZHU Bin YANG Wei WANG Kui |
Department of Orthopaedics and Traumatology, Ethnic Hospital of Enshi Tujia and Miao Autonomous Prefecture, Hubei Province, Enshi 445000, China
|
|
|
|
Abstract Objective To investigate the effect of Yiqi Huoxue Shengji Prescription on ulcer wound healing and vessel regeneration in diabetic mellitus rats. Methods Sixty male SD rats with SPF grade 281-320 g and age of eight-ten weeks were divided into drug administration group, refractory wound group, normal wound group, and Sijunzi Decoction group according to random number table method, with 15 rats in each group. Among them, the drug administration group, refractory wound group, and Sijunzi Decoction group were prepared into diabetes mellitus model by streptozutocin method, fasting blood glucose ＞16.7 mmol/L after 48 h, with the occurrence of polyuria and polydipsia, indicating successful modeling. Skin defect wounds were made on the back of all rats. The drug administration group and Sijunzi Decoction group were given 3 ml Yiqi Huoxue Shengji Prescription and Sijunzi Decoction by gavage, respectively, and the other groups were given 3 ml double steaming water by gavage, once in the morning and once in the evening. On the 5th, 10th, and 20th day after surgery, five rats in each group were selected to measure the wound size and calculate the wound healing rate. Hematoxylin-eosin staining was used to observe and calculate the number of capillaries on the ulcer wound. The content of vascular endothelial growth factor (VEGF) in the blood of rats was detected by enzyme-linked immunoadsordent assay. The content of VEGF, transforming growth factor-β1 (TGF-β1), and Smad3 in the local tissue of the wound was detected by Western blot. Results Wound healing rate, serum VEGF expression level, and VEGF protein expression level in local tissue of wound in each group on the 20th day after surgery were higher than those on the 5th and 10th day after surgery; wound healing rate, serum VEGF expression level, and VEGF protein expression level in local tissue of wound in each group on the 10th day after surgery were higher than those on the 5th day after surgery (P＜0.05). The protein expression levels of TGF-β1 and Smad3 in drug administration group and normal wound group on the 20th day after surgery were lower than those in this group on the 5th and 10th day after surgery, and the protein expression levels of TGF-β1 and Smad3 in drug administration group and normal wound group on the 10th day after surgery were lower than those in this group on the 5th day after surgery (P＜0.05). The protein expression levels of TGF-β1 in refractory wound group on the 20th day after surgery were lower than those on the 5th and 10th day after surgery (P＜0.05). The expression level of Smad3 protein in refractory wound group on the 10th and 20th day after surgery were higher than those on the 5th day after surgery (P＜0.05). On the 5th day after surgery, the wound healing rate of refractory wound group was lower than that of normal wound group (P＜0.05). On the 10th and 20th day after surgery, the wound healing rate in the refractory wound group was lower than that in the normal wound group, and the wound healing rate in the drug administration group was higher than that in the refractory wound group (P＜0.05). The serum VEGF expression level and VEGF protein expression level in local wound tissue of refractory wound group were lower than those of normal wound group at all time points after surgery, and the serum VEGF expression level and VEGF protein expression level in local wound tissue of drug administration group were higher than those of refractory wound group (P＜0.05). On the 5th and 10th day after surgery, the protein expression levels of TGF-β1 and Smad3 in refractory wound group were lower than those in normal wound group, and the protein expression levels of TGF-β1 and Smad3 in drug administration group were higher than those in refractory wound group (P＜0.05). On the 20th day after surgery, the protein expression levels of TGF-β1 and Smad3 in refractory wound group were higher than those in normal wound group, while the protein expression levels of TGF-β1 and Smad3 in drug administration group were lower than those in refractory wound group (P＜0.05). Pathological observation showed that the inflammatory cell infiltration and tissue necrosis in the drug administration group were lighter than those in the refractory wound group, and the formation of capillaries was obvious. Conclusion Yiqi Huoxue Shengji Prescription can promote the secretion of VEGF in diabetic rats, regulate the expression of TGF-β1 and Smad3 proteins, promote neovascularization, and then promote the healing of refractory wounds.
|
|
|
|
|
|
[1] Allie C，Tammy C. Chronic Wound Biofilms：Pathogenesis and Potential Therapies [J]. Lab Med，2015，46（4）：277-284.
[2] 姚泽欣，付小兵，程飚.慢性创面愈合新理念：姑息性创面治疗的研究进展[J].中华烧伤杂志，2020，36（8）：754-757.
[3] 许再杰.脂肪来源干细胞促进难愈性创面愈合的研究进展[J].山西医药杂志，2022，51（7）：765-768.
[4] 王云飞，阙华发，高丹，等.四君子加川牛膝方对大鼠下肢难愈性创面愈合的影响[J].上海中医药大学学报，2013， 27（3）：95-98.
[5] 李友山，郑琪，冀凌云，等.改良STZ法制备糖尿病足溃疡大鼠模型[J].辽宁中医杂志，2016，43（1）：158-160.
[6] 朱静，彭旦明.慢性难愈性创面的治疗研究进展[J].实用中西医结合临床，2021，21（19）：156-159.
[7] 孟浩，苏建隆，王睿，等.889例体表慢性难愈合创面住院患者临床流行病学研究[J].解放军医学院学报，2022，43（3）：253-258.
[8] 孙梦婷，封岩，蒋立军，等.医用臭氧在治疗糖尿病足慢性创面中的应用研究[J].足踝外科电子杂志，2021，8（1）：57-61，64.
[9] 李山郎，花奇凯，刘光炜，等.胫骨横向骨搬移治疗下肢难愈性创面的研究进展[J].中华骨科杂志，2021，41（11）：705-713.
[10] 周晓春，陈晓明，王惠，等.波动式负压引流技术在穿支皮瓣移植修复难愈性创面中的应用[J].中国美容医学，2022，31（2）：21-25.
[11] 王爱，马文国，王成德，等.自体富血小板血浆凝胶联合负压封闭引流技术治疗难愈性创面的临床效果[J].中华烧伤杂志，2021，37（1）：42-48.
[12] 刘华，肖东杰，高聪，等.间充质干细胞治疗慢性难愈性创面的研究进展[J].中国美容整形外科杂志，2022，33（6）：384-387.
[13] 马乐，席建元，鲍秋羽.托里消毒饮联合象皮生肌膏治疗慢性皮肤溃疡的临床研究[J].中国医药导报，2020， 17（25）：145-148.
[14] 徐旭英，杨博华，赵进喜，等.论糖尿病足中医外治法及其实践[J].北京中医药，2021，40（12）：1336-1339.
[15] 王云飞，李淑娟，杨伟朋，等.四君子加川牛膝方对大鼠下肢难愈性创面组织成纤维细胞及相关细胞因子的影响[J].上海中医药大学学报，2017，31（2）：80-84.
[16] 刘禹全，吕新亮，赵军，等.中医治疗慢性难愈性创面的研究进展[J].内蒙古中医药，2021，40（12）：167-168.
[17] 黄丽芳，许彦，唐乾利.压疮的中西医结合治疗进展[J].中国烧伤创疡杂志，2020，32（1）：12-14，25.
[18] 朱朝军，张朝晖，马静，等.生肌象皮膏在慢性难愈性创面修复中的应用研究进展[J].世界中西医结合杂志，2014， 9（10）：1136-1138.
[19] 尹少平，徐泽宇，闵文，等.中药外用制剂在慢性创面治疗中的应用与思考[J].南京中医药大学学报，2020，36（5）：690-695.
[20] 熊佳超，宋建星.脂肪来源干细胞治疗难愈性创面的研究进展[J].中国修复重建外科杂志，2018，32（4）：457-461.
[21] Dulmovits BM，Herman IM. Microvascular remodeling and wound healing：A role for pericytes [J]. Int J Biochem Cell Biol，2012，44（11）：1800-1812.
[22] 王明霞，彭艳，郑淇，等.改善微循环治疗慢性难愈性创面的中药及单体研究进展[J].世界临床药物，2021，42（11）：1006-1010.
[23] 蔡小艳，符茂雄.糖尿病足创面皮肤基质相关细胞因子研究进展[J].现代医药卫生，2022，38（12）：2055-2059.
[24] Chaudagar KK，Mehta AA. Effect of telmisartan on VEGF- induced and VEGF-independent angiogenic responsiveness of coronary endothelial cells in normal and streptozotocin（STZ）-induced diabetic rats [J]. Clin Exp Hypertens，2014，36（8）：557-566.
[25] 陈盛业，甘宇.生肌玉红膏对大鼠糖尿病足溃疡组织bFGF、HIF-1α及VEGF表达的影响[J].西部中医药，2021，34（9）：23-26.
[26] 史旭锋，魏冬，余小平，等.血管内皮生长因子介导的血管新生促进创面愈合的研究进展[J].中华损伤与修复杂志（电子版），2021，16（6）：536-538. |
|
|
|
